Showing 1821-1830 of 5643 results for "".
- Spryte Medical Receives Breakthrough Device Designation from FDA for Neuro OCT Technologyhttps://modernod.com/news/spryte-medical-receives-breakthrough-device-designation-from-fda-for-neuro-optical-coherence-tomography-noct-technology/2482373/Spryte Medical announced that its neuro Optical Coherence Tomography (nOCT) technology has been granted Breakthrough Device Designation by the FDA. This recognition underscores the potential of nOCT in neurointervention and cerebrovascular treatment. The FDA’s
- FDA Grants DeNovo Classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pumphttps://modernod.com/news/fda-grants-denovo-classification-to-balance-ophthalmics-fysxtm-ocular-pressure-adjusting-pump/2482333/Balance Ophthalmics announced that the FDA has granted DeNovo Classification of the FYSX Ocular Pressure Adjusting Pump, a new category of treatment for patients with normal tension glaucoma (NTG) and open-angle glaucoma (OAG) with IOP ≤ 21 mmHg. “The FDA classif
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eyehttps://modernod.com/news/nordic-pharma-launches-lacrifill-canalicular-gel-for-dry-eye/2482301/Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, a novel therapy for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system
- Nordic Pharma to Present Data on Lacrifill Canaliocular Gel, a Novel Therapy for Dry Eye, at ASCRShttps://modernod.com/news/nordic-pharma-to-present-data-on-lacrifill-canaliocular-gel-a-novel-therapy-for-dry-eye-at-ascrs/2482202/Nordic Pharma will be presenting data on Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston, on April 5-8, 2024. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivativ
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l